The New Yorker has a terrific piece about the degree to which new weight loss drugs are having an impact on the culture and the economy.
An excerpt:
“The science of GLP-1 agonists has often zigged, and now it might zag. GLP-1 produces all sorts of cascading effects; the human body has receptors for it not only in the gut but also in the liver, muscles, and brain. Studies keep turning up surprises: some of the medications appear to reduce the incidence of heart attacks and strokes, slow the progression of kidney disease, and shrink dangerous fat deposits in the liver. People who take them have reported diminished cravings for alcohol and tobacco; some have reported feeling less compelled to gamble, compulsively pick at their skin, and engage in other addictive behaviors.”
And, the story suggests, we’re still discovering the impact that these drugs will have on on a country where obesity is seen not just as a national health problem, but also a national security issue.
You can read the entire story here.
The post Worth Reading: “The Year Of Ozempic” appeared first on MNB.
View Original Article
